Hudson Portfolio Management LLC Buys Shares of 1,365 United Therapeutics Corporation $UTHR

Posted by Francis Steltz on Aug 23rd, 2026

Hudson Portfolio Management LLC bought a new stake in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 1,365 shares of the biotechnology company’s stock, valued at approximately $740,000.

Other large investors also recently modified their holdings of the company. Torren Management LLC purchased a new position in United Therapeutics in the fourth quarter valued at approximately $26,000. Activest Wealth Management increased its position in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after buying an additional 56 shares during the last quarter. Entrust Financial LLC purchased a new stake in United Therapeutics in the fourth quarter worth $31,000. International Assets Investment Management LLC raised its stake in shares of United Therapeutics by 426.7% in the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 64 shares during the period. Finally, Wilmington Savings Fund Society FSB raised its stake in shares of United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after buying an additional 49 shares during the period. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on UTHR. Morgan Stanley set a $515.00 price target on United Therapeutics in a research note on Thursday, August 6th. Bank of America lowered their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. Weiss Ratings raised shares of United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a report on Thursday, August 13th. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Finally, Royal Bank Of Canada cut their target price on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research report on Thursday, August 6th. Eleven research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $646.00.

View Our Latest Report on UTHR

Insider Transactions at United Therapeutics

In related news, EVP Paul A. Mahon sold 8,300 shares of the company’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $523.14, for a total value of $4,342,062.00. Following the transaction, the executive vice president directly owned 45,172 shares in the company, valued at approximately $23,631,280.08. This represents a 15.52% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $526.96, for a total transaction of $5,006,120.00. Following the completion of the sale, the chief executive officer directly owned 324,443 shares in the company, valued at $170,968,483.28. This represents a 2.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 442,575 shares of company stock valued at $239,326,330. Corporate insiders own 8.60% of the company’s stock.

United Therapeutics Stock Performance

Shares of UTHR stock opened at $513.12 on Friday. The company has a market capitalization of $22.01 billion, a PE ratio of 18.36, a price-to-earnings-growth ratio of 1.74 and a beta of 0.59. United Therapeutics Corporation has a 52-week low of $302.19 and a 52-week high of $609.35. The business’s fifty day moving average is $533.08 and its 200 day moving average is $537.36.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, topping the consensus estimate of $6.86 by $0.41. The business had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm’s revenue was down 1.9% on a year-over-year basis. During the same period in the previous year, the business earned $6.41 earnings per share. On average, sell-side analysts forecast that United Therapeutics Corporation will post 26.33 EPS for the current fiscal year.

About United Therapeutics

(Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.